Treatment of oxaliplatin-induced peripheral neuropathy with oxycodone and extension of FOLFOX in patients with advanced colorectal cancer.

e19534 Background: FOLFOX is a combination chemotherapeutic regimen that incorporates folinic acid (FOL), 5-fluorouracil (F), and oxaliplatin (OX). FOLFOX is the standard adjuvant and metastatic therapy for advanced colorectal cancer. Peripheral neuropathy (PN) is the most frequent dose-limiting toxicity of oxaliplatin. It is crucial to prevent chemotherapy-induced PN or reduce its severity for optimal treatment delivery and prolongation of survival. We retrospectively evaluated the efficacy of oxycodone in patients with oxaliplatin-induced PN. Methods: The medical records of 56 eligible patients (range 48-74 y.o.) treated at Toho University Medical Center Sakura Hospital were reviewed; of these 56 patients, 27 received oxycodone (range 10-60 mg/day, average 17.8 mg) for oxaliplatin-induced PN (OXC (+) group). Treatment was continued until disease progression, unacceptable toxicity occurred, or until patient withdrawal. Results: One patient in the OXC (-) group showed Grade 3 PN (CTCAE v4.0), other patien...